Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Single-cell spatial landscapes of the lung tumour immune microenvironmentNature (London), 2023-02, Vol.614 (7948), p.548-554 [Peer Reviewed Journal]2023. The Author(s). ;Copyright Nature Publishing Group Feb 16, 2023 ;The Author(s) 2023 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-022-05672-3 ;PMID: 36725934Full text available |
|
2 |
Material Type: Article
|
Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening TrialJournal of thoracic oncology, 2019-10, Vol.14 (10), p.1732-1742 [Peer Reviewed Journal]2019 ;Copyright © 2019 by the International Association for the Study of Lung Cancer ;Published by Elsevier Inc. ;ISSN: 1556-0864 ;EISSN: 1556-1380 ;DOI: 10.1016/j.jtho.2019.05.044 ;PMID: 31260833Full text available |
|
3 |
Material Type: Article
|
miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cellsPloS one, 2013-03, Vol.8 (3), p.e60317-e60317 [Peer Reviewed Journal]COPYRIGHT 2013 Public Library of Science ;2013 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2013 Chen et al 2013 Chen et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0060317 ;PMID: 23555954Full text available |
|
4 |
Material Type: Article
|
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung CancerThe New England journal of medicine, 2020-10, Vol.383 (18), p.1711-1723 [Peer Reviewed Journal]Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2027071 ;PMID: 32955177Full text available |
|
5 |
Material Type: Article
|
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung CancerThe New England journal of medicine, 2019-11, Vol.381 (21), p.2020-2031 [Peer Reviewed Journal]Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1910231 ;PMID: 31562796Full text available |
|
6 |
Material Type: Article
|
Adjuvant chemotherapy for resected early‐stage non‐small cell lung cancerCochrane database of systematic reviews, 2015-03, Vol.2015 (3), p.CD011430-CD011430 [Peer Reviewed Journal]Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ;ISSN: 1469-493X ;EISSN: 1465-1858 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.CD011430 ;PMID: 25730344Full text available |
|
7 |
Material Type: Article
|
Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancerPloS one, 2012-04, Vol.7 (4), p.e35065-e35065 [Peer Reviewed Journal]COPYRIGHT 2012 Public Library of Science ;COPYRIGHT 2012 Public Library of Science ;2012 Lv et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Lv et al. 2012 ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0035065 ;PMID: 22493729Full text available |
|
8 |
Material Type: Article
|
Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung CancerThe New England journal of medicine, 2022-01, Vol.386 (3), p.241-251 [Peer Reviewed Journal]Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2022 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2112431 ;PMID: 34534430Full text available |
|
9 |
Material Type: Article
|
Progress and prospects of early detection in lung cancerOpen biology, 2017-09, Vol.7 (9), p.170070 [Peer Reviewed Journal]2017 The Authors. ;2017 The Authors. 2017 ;ISSN: 2046-2441 ;EISSN: 2046-2441 ;DOI: 10.1098/rsob.170070 ;PMID: 28878044Full text available |
|
10 |
Material Type: Article
|
Antibodies against endogenous retroviruses promote lung cancer immunotherapyNature (London), 2023-04, Vol.616 (7957), p.563-573 [Peer Reviewed Journal]2023. The Author(s). ;Copyright Nature Publishing Group Apr 20, 2023 ;The Author(s) 2023 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-023-05771-9 ;PMID: 37046094Full text available |
|
11 |
Material Type: Article
|
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 studyThe lancet oncology, 2018-01, Vol.19 (1), p.139-148 [Peer Reviewed Journal]2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;COPYRIGHT 2018 Elsevier B.V. ;Copyright Elsevier Limited Jan 1, 2018 ;2018. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(17)30729-5 ;PMID: 29174310Full text available |
|
12 |
Material Type: Article
|
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trialThe lancet oncology, 2019-12, Vol.20 (12), p.1655-1669 [Peer Reviewed Journal]2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;2019. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(19)30634-5 ;PMID: 31591063Full text available |
|
13 |
Material Type: Article
|
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary CancersPloS one, 2015-06, Vol.10 (6), p.e0130142-e0130142 [Peer Reviewed Journal]COPYRIGHT 2015 Public Library of Science ;COPYRIGHT 2015 Public Library of Science ;2015 Carbognin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2015 Carbognin et al 2015 Carbognin et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0130142 ;PMID: 26086854Full text available |
|
14 |
Material Type: Article
|
The evolution of lung cancer and impact of subclonal selection in TRACERxNature (London), 2023-04, Vol.616 (7957), p.525-533 [Peer Reviewed Journal]2023. The Author(s). ;Copyright Nature Publishing Group Apr 20, 2023 ;The Author(s) 2023 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-023-05783-5 ;PMID: 37046096Full text available |
|
15 |
Material Type: Article
|
Crizotinib-induced immunogenic cell death in non-small cell lung cancerNature communications, 2019-04, Vol.10 (1), p.1486-17, Article 1486 [Peer Reviewed Journal]This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Distributed under a Creative Commons Attribution 4.0 International License ;The Author(s) 2019 ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-019-09415-3 ;PMID: 30940805Full text available |
|
16 |
Material Type: Article
|
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerThe New England journal of medicine, 2017-11, Vol.377 (20), p.1919-1929 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1709937 ;PMID: 28885881Full text available |
|
17 |
Material Type: Article
|
Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancerPloS one, 2021-12, Vol.16 (12), p.e0260988-e0260988 [Peer Reviewed Journal]COPYRIGHT 2021 Public Library of Science ;2021 Rice, Belani. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 Rice, Belani 2021 Rice, Belani ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0260988 ;PMID: 34855926Full text available |
|
18 |
Material Type: Article
|
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancerThe Journal of clinical investigation, 2019-03, Vol.129 (3), p.1211-1228 [Peer Reviewed Journal]COPYRIGHT 2019 American Society for Clinical Investigation ;COPYRIGHT 2019 American Society for Clinical Investigation ;Copyright American Society for Clinical Investigation Mar 2019 ;Copyright © 2019, American Society for Clinical Investigation 2019 American Society for Clinical Investigation ;ISSN: 0021-9738 ;EISSN: 1558-8238 ;DOI: 10.1172/jci123319 ;PMID: 30589644Full text available |
|
19 |
Material Type: Article
|
Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancerBritish journal of cancer, 2019-09, Vol.121 (6), p.490-496 [Peer Reviewed Journal]Copyright Nature Publishing Group Sep 2019 ;The Author(s), under exclusive licence to Cancer Research UK 2019 ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/s41416-019-0541-3 ;PMID: 31388183Full text available |
|
20 |
Material Type: Article
|
Metformin use and lung cancer survival: a population-based study in NorwayBritish journal of cancer, 2021-03, Vol.124 (5), p.1018-1025 [Peer Reviewed Journal]The Author(s), under exclusive licence to Cancer Research UK 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s), under exclusive licence to Cancer Research UK 2020 ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/s41416-020-01186-9 ;PMID: 33262518Full text available |